Pharmaceutical company · NVS

Novartis
clinical trial
pipeline

Registry checked

Published

Remibrutinib is linked to 21 distinct active studies, with 1 Phase 1, 2 Phase 2, 18 Phase 3. Inclisiran is linked to 16 distinct active studies, with 1 Phase 1, 8 Phase 3, 2 Phase 4, 5 without a recorded phase.

94 active trials lack a mapped primary therapeutic group. The categories and accepted programme links are partial enrichment, so individual study records provide additional context.

Active trial mix

Lead-sponsor scope

375active trials
as lead sponsor
  • Phase 144
  • Phase 295
  • Phase 396
  • Phase 424
  • Phase not recorded116

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

01 Oct 2026 – 30 Oct 2026 · UTC

Recorded changes

7447 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved later by 366 days

2027-02-28 (estimated)2028-02-29 (estimated)
28 Feb 202729 Feb 2028

Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia

NCT07684469 · ClinicalTrials.gov
Recorded by ComplyRx
30 Oct 2026
Registry last updated
30 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-010200022
2026-10-021310163
2026-10-030000442
2026-10-040000000
2026-10-050120142
2026-10-062020042
2026-10-071010021
2026-10-080000000
2026-10-090100232
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-132020042
2026-10-142100033
2026-10-153320085
2026-10-162610097
2026-10-171000011
2026-10-180000000
2026-10-190000000
2026-10-201411075
2026-10-212200043
2026-10-222010032
2026-10-231110032
2026-10-240100011
2026-10-250000000
2026-10-260000000
2026-10-270010011
2026-10-281100021
2026-10-290000000
2026-10-301200032
Type totals222815187447 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Remibrutinib

rhapsido

21
Active trials
11
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 22
  • Phase 318
  • Phase 40
  • Phase not recorded0
Studied condition
Chronic Inducible Urticaria · Chronic Pruritus of Unknown Origin · Chronic Spontaneous Urticaria
Next primary completion
03 November 2026 · estimated
Open drug

Inclisiran

LEQVIO

16
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 20
  • Phase 38
  • Phase 42
  • Phase not recorded5
Studied condition
Acute Coronary Syndrome · Atherosclerotic Cardiovascular Disease · Atherosclerotic Vascular Disease
Next primary completion
11 February 2027 · estimated
Open drug

Ianalumab

Canonical investigational asset

16
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 25
  • Phase 311
  • Phase 40
  • Phase not recorded0
Studied condition
Diffuse Cutaneous Systemic Sclerosis · Lupus Nephritis · Primary Evans Syndrome (ES)
Next primary completion
26 March 2027 · estimated
Open drug

Iptacopan

FABHALTA

12
Active trials
9
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 22
  • Phase 310
  • Phase 40
  • Phase not recorded0
Studied condition
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis · Atypical Hemolytic Uremic Syndrome · C3 Glomerulopathy
Next primary completion
30 December 2026 · estimated
Open drug

177Lu-PSMA-617

Canonical investigational asset

9
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 24
  • Phase 33
  • Phase 41
  • Phase not recorded0
Studied condition
Metastatic Castration Resistant Prostate Cancer (mCRPC) · Metastatic Castration-Resistant Prostate Cancer · Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Next primary completion
14 December 2026 · estimated
Open drug

Ribociclib

KISQALI

9
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 22
  • Phase 32
  • Phase 41
  • Phase not recorded4
Studied condition
Breast Cancer · Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies · Early Breast Cancer
Next primary completion
01 February 2027 · estimated
Open drug

261 of 375 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 261 of 375 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Novartis trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Remibrutinib

NCT05677451

Phase 3 · Active, not recruiting

Trial source and qualifications

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Duration ends at independently recorded study completion. Source date qualifications: end-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

End clipped at the display horizon.

4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

4 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 11 Jul 2023 · actual
    Primary completion: 03 Nov 2026 · estimated
    Study completion: 30 Mar 2032 · estimated

    2021202220232024202520262027202820292030
    Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
    177Lu-PSMA-617

    NCT06004661

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 6 inspected observations were not displayed.

    6 candidate observations · 0 shown · 0 recorded after primary completion · 6 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    6 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 04 Apr 2024 · actual
      Primary completion: 14 Dec 2026 · estimated
      Study completion: 14 Dec 2026 · estimated

      2021202220232024202520262027202820292030
      PSMACare
      177Lu-PSMA-617

      NCT05849298

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 5 inspected observations were not displayed.

      5 candidate observations · 0 shown · 0 recorded after primary completion · 5 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      5 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 03 Jan 2024 · actual
        Primary completion: 23 Dec 2026 · estimated
        Study completion: 23 Dec 2026 · estimated

        2021202220232024202520262027202820292030
        Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
        everolimus

        NCT02962414

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

        Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        Start clipped at the display horizon.

        1 candidate observations · 1 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        Up to three verified eligible observations in the bounded history window.

        • pc date moved · Recorded 2026-08-22 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 23 Aug 2017 · actual
        Primary completion: 30 Dec 2026 · estimated
        Study completion: 30 Dec 2026 · estimated

        2021202220232024202520262027202820292030
        Iptacopan in Patients With ANCA Associated Vasculitis
        Iptacopan

        NCT06388941

        Phase 2 · Active, not recruiting

        Trial source and qualifications

        Iptacopan in Patients With ANCA Associated Vasculitis

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

        3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        3 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 05 Aug 2024 · actual
          Primary completion: 30 Dec 2026 · estimated
          Study completion: 30 Dec 2026 · estimated

          2021202220232024202520262027202820292030
          KontRASt-01
          Opnurasib

          NCT04699188

          Phase 2 · Active, not recruiting

          Trial source and qualifications

          Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 5 inspected observations were not displayed.

          5 candidate observations · 0 shown · 0 recorded after primary completion · 5 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          5 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 24 Feb 2021 · actual
            Primary completion: 25 Jan 2027 · estimated
            Study completion: 25 Jan 2027 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 129 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 33 actual primary completions, 0 untyped primary completions, 5 past estimates, 24 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            115

            active trials in Oncology

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Oncology115 trials
            • Neurology34 trials
            • Immunology & Inflammation26 trials
            • Dermatology24 trials
            • Cardiovascular20 trials
            • Metabolic/Endocrine/Nutrition18 trials
            • Renal & Urology15 trials
            • Haematology13 trials
            • Infectious Disease5 trials
            • Respiratory4 trials
            • Anaesthesia & Perioperative Care1 trials
            • Dental & Oral1 trials
            • Gastroenterology & Hepatology1 trials
            • Genetic & Rare Disease1 trials
            • Ophthalmology1 trials
            • Psychiatry & Addiction1 trials
            • Unmapped94 trials
            • Healthy volunteers1 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies
            P

            Pfizer

            Shared indexed programme context · 1 selected asset

            Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Enumerated controlled company group covers 3,773 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Novartis · Chinook Therapeutics, Inc. (formerly Aduro). Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion. Additional Corthera coverage remains unresolved. Independent Alcon and Sandoz are excluded.

            ClinicalTrials.gov

            Attribution coverage

            3,803 distinct registry candidates produced 3,773 accepted studies. 18 mapped to other owners, 12 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 54 unverified, 2 identity-only and 52 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            3,417 scoped records have indexed enrichment and 356 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-10-31T20:23:15.490Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 65200760ed608d9dacb9e7b714c1e91bb0c088a2d0c55469eb19623a7443ea8b.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 3,773 mapped lead-sponsored clinical studies across all statuses. 3,417 have indexed enrichment, 356 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.